Newsletters

[Oncogene] Using transcriptomic profiling of fibroblasts from colorectal cancer patients, investigators identified highly expressed markers that define fibroblast subpopulations and uncover mechanisms governing their plasticity.

[European Journal of Medicinal Chemistry] The authors reported a rigid triazolyl-azabicyclo[3.1.0]hexanyl–oxadiazolyl-pyrimidine scaffold developed through structure-based design, designed to potentially enhance autotaxin selectivity by promoting defined binding geometry.

[Calcified Tissue International] To determine how CFTR specifically contributes to amelogenesis, the authors generated a conditional knockout mouse in which CFTR loss-of-function is driven by Cre expression under the promoter of the maturation-stage ameloblast marker, Odam.

[Journal of Hematology & Oncology] The authors explore how cytokines function as upstream signals that guide cancer-associated fibroblast (CAF) activation and lineage commitment, as well as downstream effectors secreted by CAFs to promote tumor cell malignancy and reprogram the tumor microenvironment.

[MannKind Corporation] MannKind Corporation announced that it has been developing a dry powder inhalation (DPI) formulation of ralinepag, known as ralinepag DPI, for United Therapeutics Corporation, under the companies’ expanded license and collaboration agreement announcement from August 2025.

[Pliant Therapeutics] Pliant Therapeutics announced the dosing of the first participant in the FORTIFY Phase Ib open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors. PLN-101095 is an oral, small molecule, dual selective inhibitor of the integrins αvβ8 and αvβ1.

[Ovarian Cancer Canada] Ovarian Cancer Canada is investing $725,000 to enable powerful natural killer cell immunotherapy that Dr. Jeanette Boudreau has been developing for many years to become “clinical trial-ready”.

[Cancer Immunology Research] Scientists found that anti-CD40–based therapy, when combined with IL10 receptor blockade, initiates a Batf3-dependent pathway in which IL12 and IFNγ secretion results in oncolytic neutrophil activity.

[Nature Biomedical Engineering] The authors reported PRIME-In, a novel genome-editing platform that uses a prime editing-engineered donor template coupled with either single or paired genomic nicks to enable precise integration of substantial DNA payloads into human cells without reliance on double-strand break repair pathways.